ATG16L1 and neoplasm: The fact that ATG5 is selectively inactivated by somatic mutations and/or alternative mRNA splicing (Figs. 1 and 3), and that ATG16L2 is transcriptionally overexpressed, relative to ATG16L1, in multiple tumor types (Fig. 5g), suggests that the inhibition of autophagy is indeed oncogenic.